Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451463 · ClinicalTrials.gov registry record
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
A clinical trial, sponsored by Ohio State University.
- Completed
- Registry status
- 11
- Enrollment target
NCT01451463 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 11 participants.
The verdict
NCT01451463 has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates. Xenazine (tetrabenazine) is a monoamine-depleting drug that is commonly used to reduce chorea. The purpose of this study is to compare: 1) spatial and temporal gait measures, 2) performance on functional mobility measures, and 3) amount of daily walking activity before and after administration of Xenazine in individuals with HD. It is hypothesized that the use of Xenazine to decrease chorea will improve functions of 1) gait, 2) sit-to-stand transfers 3) stair climbing and 4) overall daily physical activity and function.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01451463
The ClinicalTrials.gov registry entry for NCT01451463 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01451463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01451463 about?
NCT01451463 is a clinical study titled "Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease". In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates. Xenazine (tetrabenazine) is a monoamine-depleting drug that is commonly used to reduce cho...
What is the current status of trial NCT01451463?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2010-04. Estimated completion is 2013-04.
Who is sponsoring clinical trial NCT01451463?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.